The Department of Health and Human Services is rolling out a series of regulatory reforms designed to make the United States a more attractive destination for early-phase drug trials. The initiative, announced Tuesday, responds directly to the competitive pressure from China's rapidly expanding biopharmaceutical sector.
The planned changes target the administrative and logistical hurdles that have driven many sponsors to conduct first-in-human studies overseas. By streamlining review processes and reducing bureaucratic delays, HHS hopes to reverse a trend where a growing share of early clinical work migrates to lower-cost, faster-moving regulatory environments abroad.